KR20220154709A - 분말형 비강내 에피네프린으로의 치료 - Google Patents

분말형 비강내 에피네프린으로의 치료 Download PDF

Info

Publication number
KR20220154709A
KR20220154709A KR1020227033697A KR20227033697A KR20220154709A KR 20220154709 A KR20220154709 A KR 20220154709A KR 1020227033697 A KR1020227033697 A KR 1020227033697A KR 20227033697 A KR20227033697 A KR 20227033697A KR 20220154709 A KR20220154709 A KR 20220154709A
Authority
KR
South Korea
Prior art keywords
epinephrine
pharmaceutical composition
type
particles
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227033697A
Other languages
English (en)
Korean (ko)
Inventor
갈리아 템친-크라이즈
파벨 카즈단
Original Assignee
나수스 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나수스 파마 리미티드 filed Critical 나수스 파마 리미티드
Publication of KR20220154709A publication Critical patent/KR20220154709A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
KR1020227033697A 2020-03-16 2021-03-16 분말형 비강내 에피네프린으로의 치료 Withdrawn KR20220154709A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US62/989,913 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
US17/135,528 2020-12-28
PCT/IL2021/050288 WO2021186437A1 (en) 2020-03-16 2021-03-16 Treatment with powdered intranasal epinephrine

Publications (1)

Publication Number Publication Date
KR20220154709A true KR20220154709A (ko) 2022-11-22

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033697A Withdrawn KR20220154709A (ko) 2020-03-16 2021-03-16 분말형 비강내 에피네프린으로의 치료

Country Status (13)

Country Link
US (2) US11400045B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121005A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023517532A (cg-RX-API-DMAC7.html)
KR (1) KR20220154709A (cg-RX-API-DMAC7.html)
CN (1) CN115279340A (cg-RX-API-DMAC7.html)
AR (1) AR121593A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021239084A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018440A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175130A1 (cg-RX-API-DMAC7.html)
IL (1) IL296268A (cg-RX-API-DMAC7.html)
MX (1) MX2022011464A (cg-RX-API-DMAC7.html)
TW (1) TW202200119A (cg-RX-API-DMAC7.html)
WO (1) WO2021186437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12661315B2 (en) 2021-06-10 2026-06-23 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
AU2023322235A1 (en) * 2022-08-11 2025-03-13 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
KR20260016535A (ko) * 2023-05-31 2026-02-03 오렉쏘 에이비 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물
US20260108465A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940006601A (ko) 1992-09-12 1994-04-25 야나가와 히로미 생리활성 펩티드 조성물
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
ATE289825T1 (de) 1999-04-21 2005-03-15 1355540 Ontario Inc Methacoline oder histamine formulierungen zur feststellung von asthma
GB2367756B (en) 2000-10-12 2003-01-08 Bespak Plc Dispensing apparatus
GB2380410B (en) 2001-10-05 2003-11-19 Alchemy Healthcare Ltd Apparatus for the nasal or oral delivery of a medicament
GB2384190A (en) 2002-01-22 2003-07-23 Bespak Plc Dispensing device for a powdered product
US20090246281A1 (en) 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
GB0524194D0 (en) 2005-11-28 2006-01-04 Univ Aston Respirable powders
EP1960022A1 (en) 2005-11-29 2008-08-27 Alza Corporation Nasal delivery device for the delivery of a substance to the olfactory region
US20070178166A1 (en) 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
WO2009050726A2 (en) 2007-05-28 2009-04-23 Panacea Biotec Limited Compositions and methods for improved delivery of bupropion
RU2491067C2 (ru) 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
WO2012078804A1 (en) 2010-12-07 2012-06-14 Respira Therapeutics, Inc. Dry powder inhaler
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2014134070A1 (en) 2013-02-26 2014-09-04 Baxter International Inc. Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
CN104274426A (zh) 2013-07-03 2015-01-14 陆克塞纳医药公司 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途
US20160220489A1 (en) 2013-09-03 2016-08-04 G2B Pharma Inc. Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions
CN105979999B (zh) 2013-12-11 2021-03-12 株式会社Jms 阳型连接器
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
UA121874C2 (uk) 2015-02-17 2020-08-10 Елі Ліллі Енд Компані Порошкова назальна композиція для лікування гіпоглікемії
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
CN110996912A (zh) * 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
US11844859B2 (en) * 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
ES2791775B2 (es) * 2018-02-06 2023-01-20 Aegis Therapeutics Llc Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
KR20200125632A (ko) * 2018-02-26 2020-11-04 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 분말 제제, 카트리지 및 디바이스
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Also Published As

Publication number Publication date
AU2021239084A1 (en) 2022-10-13
US12678402B2 (en) 2026-07-14
US11400045B2 (en) 2022-08-02
BR112022018440A2 (pt) 2022-11-01
US20230105615A1 (en) 2023-04-06
WO2021186437A1 (en) 2021-09-23
MX2022011464A (es) 2022-11-14
EP4121005A1 (en) 2023-01-25
TW202200119A (zh) 2022-01-01
AR121593A1 (es) 2022-06-22
CA3175130A1 (en) 2021-09-23
IL296268A (en) 2022-11-01
JP2026094260A (ja) 2026-06-09
US20210283050A1 (en) 2021-09-16
CN115279340A (zh) 2022-11-01
JP2023517532A (ja) 2023-04-26

Similar Documents

Publication Publication Date Title
US11400045B2 (en) Treatment with powdered intranasal epinephrine
CN110996912A (zh) 用于鼻内递送的干粉组合物
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
CN105101955B (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
KR20030038541A (ko) 안정한 약물 전달용 금속 이온-지질 분말 약제학적 조성물및 그것의 사용 방법
AU2022395916A1 (en) Pharmaceutical device for use in intranasal administration
JP2005520847A (ja) 肺投与用hGH(ヒト成長ホルモン)製剤
CN116549389A (zh) 鼻内肾上腺素制剂及治疗疾病的方法
EP4551196A1 (en) Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
US20140377365A1 (en) Sustained-release formulation of rotigotine
KR19990021931A (ko) 미세구형 전분의 항편두통 조성물
CN121648089A (zh) 一种缓释的西维来司他组合物及其制备方法
CN107847482A (zh) 喷雾器用组合物
BR112017007182B1 (pt) Composição farmacêutica para uso inalatório na forma de pó e kit compreendendo a referida composição

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203